Why Aren't International Blockbuster Shingles Vaccines Selling Well in China?

Market paradox: global hit, local chill

GSK’s Shingrix (欣安立适) is a global blockbuster — it has been reported that 2025 sales topped £3.558 billion (about $4.7 billion) and more than 100 million doses have been given since its 2017 launch. Yet in China the same product is struggling. It has been reported that, facing weak demand and price pressure, Shingrix’s distributor in China, Zhifei Biological (智飞生物), and GSK began “buy one, get one” promotions in 2025 that roughly halve the out‑of‑pocket cost for two doses, a dramatic step for a vaccine that dominates international adult immunization markets.

Clinical need meets commercial friction

The clinical case for vaccination in China is strong: studies and national consensus documents show shingles incidence rises sharply with age, with an estimated 15 million new cases in 2023 and lifetime risk above 30%. Shingrix’s efficacy in older adults is above 90% in trials — a key reason for its global success. But China now has a domestic challenger: Ganwei (感维), developed by Baike Biotech (百克生物), a single‑dose live attenuated vaccine approved in 2023 and initially priced to compete. Ganwei is cheaper and expands the eligible age downward to 40, but as a live vaccine it cannot be used in immunocompromised patients and its long‑term effectiveness appears lower than the recombinant option.

Why uptake lags

Several concrete barriers explain the gap. Public awareness is low: surveys show most middle‑aged and elderly Chinese underestimate their risk or wrongly assume one infection confers lifelong protection. Cost matters: Shingrix initially carried a >¥3,200 two‑dose price tag, and even after promotions still requires significant out‑of‑pocket spending; Ganwei’s lower price helped but concerns about comparative efficacy persist. It has been reported that Baike even disclosed a rare “negative sales” quarter in 2025 after returns of near‑expiry doses and price adjustments, underscoring volatile demand. A structural problem compounds this: treatment of acute shingles is typically reimbursed by basic medical insurance in China, while preventive vaccination is not — a “treatment‑oriented” payment system that blunts demand for costly self‑paid prevention.

Policy and market outlook

The situation highlights a broader policy choice: will China move vaccines like shingles into reimbursement schemes or continue to rely on out‑of‑pocket markets and price competition? Domestic producers and aggressive pricing have made vaccines available, but availability has not yet translated into high uptake. If policymakers treat adult vaccination as public‑health prevention rather than optional consumer spending, uptake could rise rapidly — and the market that looks so large from overseas may finally open. For now the international success of Shingrix collides with local economics, knowledge gaps and payment rules — a reminder that a global clinical win does not automatically equal commercial success in China.